{"id":205,"date":"2010-05-04T14:42:00","date_gmt":"2010-05-04T13:42:00","guid":{"rendered":"https:\/\/blogs.bmj.com\/heart-journalscan\/?p=205"},"modified":"2015-11-12T14:01:25","modified_gmt":"2015-11-12T13:01:25","slug":"novel-blood-pressure-agent-shows-promise","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/","title":{"rendered":"Novel blood pressure agent shows promise"},"content":{"rendered":"<p>Natriuretic peptides have a number of beneficial vascular effects: vasodilator and natriuretic properties, reduced sympathetic drive, antiproliferative effects, and inhibition of the renin-angiotensin-aldosterone (RAAS) system. \u00a0Inhibition of neprilysin (neutral endopeptidase 24.11) leads to an increase in natriuretic peptide levels, however on its own this mechanism does not lead to a clinically significant decrease in blood pressure. \u00a0However, concomitant administration of an inhibitor of the RAAS system could potentially eliminate this problem, thus a novel dual acting neprilysin and RASS ininhibitor labelled LCZ696 was investigated in this study.<!--more--><\/p>\n<p>1215 patients completed eight-weeks treatment with LCZ696. \u00a0All patients had mild-to-moderate hypertension and were randomly assigned to LCZ696 at various doses, valsartan, a neprilysin inhibitor on its own, or placebo. \u00a0Compared to treatment with valsartan alone, patients taking LCZ696 showed significantly greater reductions in mean sitting diastolic blood pressure (mean reduction -2.17mm Hg, P&lt;0.0001, figure), sitting and ambulatory pulse pressure, and 24-hour ambulatory systolic blood pressure. \u00a0LCX696 was well tolerated, and no cases of angio-oedema were reported with the drug \u2013 this had been a problem with a previous neprilysin inhibitor compound, omapatrilat.<\/p>\n<p>Conclusions:<\/p>\n<p>LCZ696, a novel anti-hypertensive that inhibits both neprilysin and angiotensin receptors, provided complementary and additive blood pressure reduction when compared to the use of valsartan alone. \u00a0Larger scale trials are now needed, but this novel therapeutic approach could potentially confer combined cardiac, vascular and renal protection.<\/p>\n<p>\u2022 Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-Pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, Mar 15.<\/p>\n<p>atriuretic peptides have a number of beneficial vascular effects: vasodilator and natriuretic properties, reduced sympathetic drive, antiproliferative effects, and inhibition of the renin-angiotensin-aldosterone (RAAS) system. \u00a0Inhibition of neprilysin (neutral endopeptidase 24.11) leads to an increase in natriuretic peptide levels, however on its own this mechanism does not lead to a clinically significant decrease in blood pressure. \u00a0However, concomitant administration of an inhibitor of the RAAS system could potentially eliminate this problem, thus a novel dual acting neprilysin and RASS ininhibitor labelled LCZ696 was investigated in this study.1215 patients completed eight-weeks treatment with LCZ696. \u00a0All patients had mild-to-moderate hypertension and were randomly assigned to LCZ696 at various doses, valsartan, a neprilysin inhibitor on its own, or placebo. \u00a0Compared to treatment with valsartan alone, patients taking LCZ696 showed significantly greater reductions in mean sitting diastolic blood pressure (mean reduction -2.17mm Hg, P&lt;0.0001, figure), sitting and ambulatory pulse pressure, and 24-hour ambulatory systolic blood pressure. \u00a0LCX696 was well tolerated, and no cases of angio-oedema were reported with the drug \u2013 this had been a problem with a previous neprilysin inhibitor compound, omapatrilat.Conclusions:LCZ696, a novel anti-hypertensive that inhibits both neprilysin and angiotensin receptors, provided complementary and additive blood pressure reduction when compared to the use of valsartan alone. \u00a0Larger scale trials are now needed, but this novel therapeutic approach could potentially confer combined cardiac, vascular and renal protection.\u2022 Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-Pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, Mar 15.<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/heart-journalscan\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/novel-blood-pressure-agent-shows-promise-figure-1-2\/\" rel=\"attachment wp-att-209\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-209\" title=\"Novel blood pressure agent shows promise figure 1\" src=\"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/05\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg\" alt=\"\" width=\"635\" height=\"756\" \/><\/a><\/p>\n<p>Mean Sitting Systolic (Top) and Diastolic Blood pressure changes<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Natriuretic peptides have a number of beneficial vascular effects: vasodilator and natriuretic properties, reduced sympathetic drive, antiproliferative effects, and inhibition of the renin-angiotensin-aldosterone (RAAS) system. \u00a0Inhibition of neprilysin (neutral endopeptidase 24.11) leads to an increase in natriuretic peptide levels, however on its own this mechanism does not lead to a clinically significant decrease in blood [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":103,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[279],"tags":[],"class_list":["post-205","post","type-post","status-publish","format-standard","hentry","category-general-cardiology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novel blood pressure agent shows promise - Heart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel blood pressure agent shows promise - Heart\" \/>\n<meta property=\"og:description\" content=\"Natriuretic peptides have a number of beneficial vascular effects: vasodilator and natriuretic properties, reduced sympathetic drive, antiproliferative effects, and inhibition of the renin-angiotensin-aldosterone (RAAS) system. \u00a0Inhibition of neprilysin (neutral endopeptidase 24.11) leads to an increase in natriuretic peptide levels, however on its own this mechanism does not lead to a clinically significant decrease in blood [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/\" \/>\n<meta property=\"og:site_name\" content=\"Heart\" \/>\n<meta property=\"article:published_time\" content=\"2010-05-04T13:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-11-12T13:01:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/05\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Novel blood pressure agent shows promise\",\"datePublished\":\"2010-05-04T13:42:00+00:00\",\"dateModified\":\"2015-11-12T13:01:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/\"},\"wordCount\":543,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/05\\\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg\",\"articleSection\":[\"General cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/\",\"name\":\"Novel blood pressure agent shows promise - Heart\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/05\\\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg\",\"datePublished\":\"2010-05-04T13:42:00+00:00\",\"dateModified\":\"2015-11-12T13:01:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/05\\\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/05\\\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/05\\\/04\\\/novel-blood-pressure-agent-shows-promise\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novel blood pressure agent shows promise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"name\":\"Heart\",\"description\":\"Highlighted articles from non-cardiological journals relevant to cardiology\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\",\"name\":\"Heart\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"width\":145,\"height\":34,\"caption\":\"Heart\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novel blood pressure agent shows promise - Heart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/","og_locale":"en_US","og_type":"article","og_title":"Novel blood pressure agent shows promise - Heart","og_description":"Natriuretic peptides have a number of beneficial vascular effects: vasodilator and natriuretic properties, reduced sympathetic drive, antiproliferative effects, and inhibition of the renin-angiotensin-aldosterone (RAAS) system. \u00a0Inhibition of neprilysin (neutral endopeptidase 24.11) leads to an increase in natriuretic peptide levels, however on its own this mechanism does not lead to a clinically significant decrease in blood [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/","og_site_name":"Heart","article_published_time":"2010-05-04T13:42:00+00:00","article_modified_time":"2015-11-12T13:01:25+00:00","og_image":[{"url":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/05\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/"},"author":{"name":"","@id":""},"headline":"Novel blood pressure agent shows promise","datePublished":"2010-05-04T13:42:00+00:00","dateModified":"2015-11-12T13:01:25+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/"},"wordCount":543,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/05\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg","articleSection":["General cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/","url":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/","name":"Novel blood pressure agent shows promise - Heart","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/05\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg","datePublished":"2010-05-04T13:42:00+00:00","dateModified":"2015-11-12T13:01:25+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#primaryimage","url":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/05\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg","contentUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/05\/Novel-blood-pressure-agent-shows-promise-figure-11.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/05\/04\/novel-blood-pressure-agent-shows-promise\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/heart\/"},{"@type":"ListItem","position":2,"name":"Novel blood pressure agent shows promise"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/heart\/#website","url":"https:\/\/blogs.bmj.com\/heart\/","name":"Heart","description":"Highlighted articles from non-cardiological journals relevant to cardiology","publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/heart\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/heart\/#organization","name":"Heart","url":"https:\/\/blogs.bmj.com\/heart\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","contentUrl":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","width":145,"height":34,"caption":"Heart"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blogs.bmj.com\/heart\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/users\/103"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/comments?post=205"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/205\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/media?parent=205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/categories?post=205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/tags?post=205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}